Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

South Africa delays COVID vaccine deliveries as inoculations slow

11/24/2021 | 06:40am EST

JOHANNESBURG, Nov 24 (Reuters) - South Africa has asked Johnson & Johnson and Pfizer to delay delivery of COVID-19 vaccines because it now has too much stock, health ministry officials said, as vaccine hesitancy slows an inoculation campaign.

About 35% of adult South Africans are fully vaccinated, higher than in most other African nations, but half the government's year-end target. It has averaged 106,000 doses a day in the past 15 days in a nation of 60 million people.

Earlier this year the programme was slowed by insufficient doses. Now deliveries have been delayed due to oversupply.

Across Africa, vaccination rates are lower than much of the rest of the world, with many countries struggling to secure enough doses. But some countries are now seeing rising supplies while vaccine campaigns are not gathering pace, such as Kenya.

Nicholas Crisp, deputy director-general of the Health Department, told Reuters that South Africa had 16.8 million doses in stock and said deliveries had been deferred.

"We have 158 days' stock in the country at current use," a spokesman for the Health Ministry said. "We have deferred some deliveries."

They did not say when deliveries would now take place.

Stavros Nicolaou, a senior executive of Aspen Pharmacare , which is packaging 25 million doses a month of J&J vaccines in South Africa, said most of the vaccines bound for South Africa would now go to the rest of the continent.

Nicolaou, who is also chairman of public health at business lobby Business for South Africa (B4SA), said deliveries would likely be deferred until the first quarter of next year.

Vaccines packaged at Aspen's plant are part of the African Union's agreement to buy 220 million doses from J&J.

The AU and J&J did not respond to emailed requests for comment.

A Pfizer spokesperson said: "We remain adaptable to individual country's vaccine requirements whilst continuing to meet our quarterly commitments as per the South Africa supply agreement."

South Africa's government has been seeking to boost the rate of daily administered doses.

"There is a fair amount of apathy and hesitancy," said Shabir Madhi, who led the clinical study for the AstraZeneca COVID-19 vaccine in South Africa.

To ramp up vaccinations, the government has launched pop-up vaccination centres and sought help from community leaders. It has also opened inoculations to children aged 12 to 17.

In Kenya, the Health Ministry said on Sunday vaccinations were moving too slowly among some parts of the population. Its statement did not mention any plan to delay any deliveries.

"We are ... concerned that only 18% of the elderly population is fully vaccinated and that vaccine uptake has generally slowed down in several counties following the lifting of the curfew last month," Health Minister Mutahi Kagwe said.

(Reporting by Promit Mukherjee; Additional reporting by Maggie Fick; Editing by Josephine Mason and Edmund Blair)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASPEN PHARMACARE HOLDINGS LIMITED -2.48% 219.93 End-of-day quote.-2.01%
ASTRAZENECA PLC 2.65% 8770 Delayed Quote.-1.54%
All news about ASTRAZENECA PLC
07:00aCORRECTING and REPLACING ENHERTU« granted Priority Review in the US for patients with H..
BU
04:37aEnhertu granted Priority Review in the US for patients with HER2-positive metastatic br..
AQ
03:01aCline Scientific extends collaboration agreement with AstraZeneca
AQ
02:40aAstraZeneca's Enhertu Granted Priority Review by US Regulator
DJ
02:31aJens Lindberg takes office as CEO of Medivir on January 24
AQ
02:23aAstraZeneca-Daiichi Sankyo's Breast Cancer Drug Accepted For Priority Review in US
MT
02:06aProsecution Takes Over Case of 8 Medics Pinned for Misusing Covid-19 Vaccines
AQ
01:09aIsrael Reopens Borders To Entry By Foreign Nationals
AQ
01/14EMA lists rare spinal condition as side effect of AstraZeneca's COVID-19 shot
RE
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 079 M - -
Net income 2021 2 716 M - -
Net Debt 2021 24 814 M - -
P/E ratio 2021 54,7x
Yield 2021 2,35%
Capitalization 185 B 186 B -
EV / Sales 2021 5,83x
EV / Sales 2022 4,78x
Nbr of Employees 76 100
Free-Float -
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 119,68 $
Average target price 138,50 $
Spread / Average Target 15,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-1.54%181 019
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317